Rho kinase inhibition activates the homologous angiotensin-converting enzyme-angiotensin-(1-9) axis in experimental hypertension

Journal of Hypertension

Volumn 29, Issue 4, 2011, Pages 706-715

  Ocaranza, María P ^a   Rivera, Paulina ^a   Novoa, Ulises ^a   Pinto, Melissa ^a   González, Leticia ^a   Chiong, Mario ^b   Lavandero, Sergio ^b,c,d   Jalil, Jorge E ^a  

^a PONTIFICIA UNIVERSIDAD CATÓLICA DE CHILE   (Chile)

^b Centro FONDAP Estudios Moleculares de la Celula   (Chile)

^c UNIVERSITY OF CHILE   (Chile)

^d UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

Author keywords

angiotensin (1 9); angiotensin converting enzyme; arterial wall; fasudil; homologous angiotensinconverting enzyme; hypertension; renin angiotensin system; Rho kinase

Indexed keywords

ANGIOTENSIN; ANGIOTENSIN CONVERTING ENZYME 2; ANGIOTENSIN II; ANGIOTENSIN[1-9]; ENDOTHELIAL NITRIC OXIDE SYNTHASE; FASUDIL; MESSENGER RNA; MONOCYTE CHEMOTACTIC PROTEIN 1; PLASMINOGEN ACTIVATOR INHIBITOR 1; RHO KINASE; TRANSFORMING GROWTH FACTOR BETA1; UNCLASSIFIED DRUG;

ANGIOTENSIN BLOOD LEVEL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIHYPERTENSIVE ACTIVITY; AORTA WALL; ARTICLE; CONTROLLED STUDY; DRUG EFFECT; ENZYME ACTIVITY; ENZYME INHIBITION; GENE EXPRESSION; HYPERTENSION; MALE; NONHUMAN; PRIORITY JOURNAL; RAT; SIGNAL TRANSDUCTION;

EID: 79952755311     PISSN: 02636352     EISSN: None     Source Type: Journal    
DOI: 10.1097/HJH.0b013e3283440665     Document Type: Article

References (52)

1. Donoghue M, Hsieh F, Baronas E, Godbout K, Gosselin M, Stagliano N, et al. A novel angiotensin-converting enzyme-related carboxypeptidase (ACE2) converts angiotensin I to angiotensin 1-9. Circ Res 2000; 87:E1-E9.
2. Turner AJ, Tipnis SR, Guy JL, Rice G, Hooper NM. ACEH/ACE2 is a novel mammalian metallocarboxypeptidase and a homologue of angiotensinconverting enzyme insensitive to ACE inhibitors. Can J Physiol Pharmacol 2002; 80:346-353. (Pubitemid 34451252)
3. Ingelfinger JR. Angiotensin-converting enzyme 2: implications for blood pressure and kidney disease. Curr Opin Nephrol Hypertens 2009; 18:79-84.
4. Crackower MA, Sarao R, Oudit GY, Yagil C, Kozieradzki I, Scanga SE, et al. Angiotensin-converting enzyme 2 is an essential regulator of heart function. Nature 2002; 417:822-828. (Pubitemid 34670323)
5. Ocaranza MP, Godoy I, Jalil JE, Varas M, Collantes P, Pinto M, et al. Enalapril attenuates downregulation of angiotensin-converting enzyme 2 in the late phase of ventricular dysfunction in myocardial infarcted rat. Hypertension 2006; 48:572-578. (Pubitemid 44843858)
6. Donoghue M, Wakimoto H, Maguire CT, Acton S, Hales P, Stagliano N, et al. Heart block, ventricular tachycardia, and sudden death in ACE2 transgenic mice with downregulated connexins. J Mol Cell Cardiol 2003; 35:1043-1053. (Pubitemid 37083248)
7. Jacobs M, Hayakawa K, Swenson L, Bellon S, Fleming M, Taslimi P, Doran J. The structure of dimeric ROCK I reveals the mechanism for ligand selectivity. J Biol Chem 2006; 281:260-268. (Pubitemid 43671185)
8. Shimokawa H, Takeshita A. Rho-kinase is an important therapeutic target in cardiovascular medicine. Arterioscler Thromb Vasc Biol 2005; 25:1767-1775. (Pubitemid 41243442)
9. Jalil JE, Lavandero S, Chiong M, Ocaranza MP. Rho/Rho kinase signal transduction pathway in cardiovascular disease and cardiovascular remodeling. Rev Esp Cardiol 2005; 58:951-961. (Pubitemid 41419170)
10. Mukai Y, Shimokawa H, Matoba T, Kandabashi T, Satoh S, Hiroki J, et al. Involvement of Rho-kinase in hypertensive vascular disease: a novel therapeutic target in hypertension. FASEB J 2001; 15:1062-1064.
11. Fukata Y, Amano M, Kaibuchi K. Rho-Rho-kinase pathway in smooth muscle contraction and cytoskeletal reorganization of nonmuscle cells. Trends Pharmacol Sci 2001; 22:32-39. (Pubitemid 32126284)
12. Hall A. Rho GTPase and the actin cytoskeleton. Science 1998; 279:509-514.
13. Amano M, Chihara K, Kimura K, Fukata Y, Nakamura N, Matsuura Y, Kaibuchi K. Formation of actin stress fibers and focal adhesions enhanced by Rho-kinase. Science 1997; 275:1308-1311. (Pubitemid 27114159)
14. van Nieuw Amerongen GP, van Hinsbergh VWM. Cytoskeletal effects of Rho-like small guanine nucleotide-binding proteins in the vascular system. Arterioscler Thromb Vasc Biol 2001; 21:300-311. (Pubitemid 32199110)
15. Horwitz AR, Parsons JT. Cell migration: movin' on. Science 1999; 286:1102-1103.
16. Narumiya S. The small GTPase Rho: cellular functions and signal transduction. J Biochem (Tokyo) 1996; 120:215-228. (Pubitemid 26335910)
17. Lee DL, Clinton Webb R, Jin L. Hypertension and RhoA/Rho kinase signaling in the vasculature. Hypertension 2004; 44:796-799.
18. Calò LA, Pessina AC. RhoA/Rho-kinase pathway: much more than just a modulation of vascular tone. Evidence from studies in humans. J Hypertens 2007; 25:259-264. (Pubitemid 46071919)
19. Shimokawa H, Rashid M. Development of Rho-kinase inhibitors for cardiovascular medicine. Trends Pharm Sci 2007; 28:296-302. (Pubitemid 46818464)
20. Sehon CA, Wang GZ, Viet AQ, Goodman KB, Dowdell SE, Elkins PA, et al. Potent, selective and orally bioavailable dihydropyrimidine inhibitors of Rho kinase (ROCK1) as potential therapeutic agents for cardiovascular diseases. J Med Chem 2008; 51:6631-6634.
21. Goodman KB, Cui H, Dowdell SE, Gaitanopoulos DE, Ivy RL, Sehon CA, et al. Development of dihydropyridone indazole amides as selective Rhokinase inhibitors. J Med Chem 2007; 50:6-9. (Pubitemid 46105495)
22. Stavenger RA, Cui H, Dowdell SE, Franz RG, Gaitanopoulos DE, Goodman KB, et al. Discovery of aminofurazan-azabenzimidazoles as inhibitors of Rho-kinase with high kinase selectivity and antihypertensive activity. J Med Chem 2007; 50:2-5. (Pubitemid 46105494)
23. Rivera P, Ocaranza MP, Lavandero S, Jalil JE. Rho kinase activation and gene expression related to vascular remodeling in normotensive rats with high angiotensin I converting enzyme levels. Hypertension 2007; 50:792-798. (Pubitemid 47442747)
24. Ocaranza MP, Piddo AM, Faú ndez P, Lavandero S, Jalil JE. Angiotensin I-converting enzyme gene polymorphism influences chronic hypertensive response in the rat Goldblatt model. J Hypertens 2002; 20:413-420. (Pubitemid 34913740)
25. Seko T, Ito M, Kureishi Y, Okamoto R, Moriki N, Onishi K, et al. Activation of Rho A and inhibition of myosin phosphatase as important components in hypertension in vascular smooth muscle. Circ Res 2003; 92:411-418. (Pubitemid 36298201)
26. Song J, Kost CK Jr, Martin DS. Androgens potentiate renal vascular responses to angiotensin II via amplification of the Rho kinase signaling pathway. Cardiovasc Res 2006; 72:456-463. (Pubitemid 44665853)
27. Sun GP, Kohno M, Guo P, Nagai Y, Miyata K, Fan YY, et al. Involvements of Rho-kinase and TGF-beta pathways in aldosterone-induced renal injury. J Am Soc Nephrol 2006; 17:2193-2201. (Pubitemid 44141909)
28. Oka M, Homma N, Taraseviciene-Stewart L, Morris KG, Kraskauskas D, Burns N, et al. Rho kinase-mediated vasoconstriction is important in severe occlusive pulmonary arterial hypertension in rats. Circ Res 2007; 100:923-929. (Pubitemid 46555698)
29. Oliveri C, Ocaranza MP, Campos X, Lavandero S, Jalil JE. Angiotensin I-converting enzyme modulates neutral endopeptidase activity in the rat. Hypertension 2001; 38:650-654.
30. Campbell DJ, Kladis A, Duncan AM. Effects of converting enzyme inhibitors on angiotensin and bradykinin peptides. Hypertension 1994; 23:439-449. (Pubitemid 24102039)
31. Jalil JE, Pé rez A, Ocaranza MP, Bargetto J, Galaz A, Lavandero S. Increased aortic NADPH oxidase activity in rats with genetically high angiotensinconverting enzyme levels. Hypertension 2005; 46:1362-1367. (Pubitemid 43189736)
32. Johns DG, Dorrance AM, Leite R, Weber DS, Webb RC. Novel signaling pathways contributing to vascular changes in hypertension. J Biomed Sci 2000; 7:431-443.
33. Uehata M, Ishizaki T, Satoh H, Ono T, Kawahara T, Morishita T, et al. Calcium sensitization of smooth muscle mediated by a Rho-associated protein kinase in hypertension. Nature 1997; 389:990-994. (Pubitemid 27485693)
34. Kaibuchi K, Kuroda S, Amano M. Regulation of the cytoskeleton and cell adhesion by the Rho family GTP-ases in mammalian cells. Annu Rev Biochem 1999; 68:459-486. (Pubitemid 29449200)
35. Mallat Z, Gojova A, Sauzeau V, Brun V, Silvestre JS, Esposito B, et al. Rhoassociated protein kinase contributes to early atherosclerotic lesion formation in mice. Circ Res 2003; 93:884-888. (Pubitemid 37363063)
36. Sauzeau V, Rolli-Derkinderen M, Marionneau C, Loirand G, Pacaud P. RhoA expression is controlled by nitric oxide through cGMP-dependent protein kinase activation. J Biol Chem 2003; 278:9472-9480. (Pubitemid 36800439)
37. Tipnis SR, Hooper NM, Hyde R, Karran E, Christie G, Turner AJ. A human homolog of angiotensin-converting enzyme. Cloning and functional expression as a captopril-insensitive carboxypeptidase. J Biol Chem 2000; 275:33238-33243.
38. Iyer SN, Yamada K, Diz DI, Ferrario CM, Chappell MC. Evidence that prostaglandins mediate the antihypertensive actions of angiotensin-(1-7) during chronic blockade of the renin-angiotensin system. J Cardiovasc Pharmacol 2000; 36:109-117. (Pubitemid 30419130)
39. Santos RA, Simoes e Silva AC, Maric C, Silva DM, Machado RP, de Buhr I, et al. Angiotensin-(1-7) is an endogenous ligand for the G protein-coupled receptor Mas. Proc Natl Acad Sci USA 2003; 100:8258-8263. (Pubitemid 36842532)
40. Erdös EG, Jackman HL, Brovkovych V, Tan F, Deddish PA. Products of angiotensin I hydrolysis by human cardiac enzymes potentiate bradykinin. J Mol Cell Cardiol 2002; 34:1569-1576. (Pubitemid 35454473)
41. Yagil Y, Yagil C. Hypothesis: ACE2 modulates blood pressure in the mammalian organism. Hypertension 2003; 41:871-873. (Pubitemid 36418458)
42. Drummer O, Kourtis S, Johnson H. Effect of chronic enalapril treatment on enzymes responsible for the catabolism of angiotensin I and formation of angiotensin II. Biochem Pharmacol 1990; 39:513-518. (Pubitemid 20041920)
43. Johnson H, Kourtis S, Waters J, Drummer OH. Radioimmunoassay for immunoreactive [des-Leu10]-angiotensin I. Peptides 1989; 10:489-492.
44. Jackman HI, Massad MG, Sekosan M, Tan F, Brovkovych V, Marcie BM, et al. Angiotensin 1-9 and 1-7 release in human heart: role of cathepsin A. Hypertension 2002; 39:976-981. (Pubitemid 34547796)
45. Ocaranza MP, Lavandero S, Jalil JE, Moya J, Pinto M, Novoa U, et al. Angiotensin-(1-9) regulates cardiac hypertrophy in vivo and in vitro. J Hypertens 2010; 28:1054-1064.
46. Sluimer JC, Gasc JM, Hamming I, van Goor H, Michaud A, van den Akker LH, et al. Angiotensin-converting enzyme 2 (ACE2) expression and activity in human carotid atherosclerotic lesions. J Pathol 2008; 215:273-279. (Pubitemid 351956708)
47. Li F, Xia W, Yuan S, Sun R. Acute inhibition of Rho-kinase attenuates pulmonary hypertension in patients with congenital heart disease. Pediatr Cardiol 2009; 30:363-366.
48. Ishikura K, Yamada N, Ito M, Ota S, Nakamura M, Isaka N, Nakano T. Beneficial acute effects of Rho-kinase inhibitor in patients with pulmonary arterial hypertension. Circ J 2006; 70:174-178. (Pubitemid 43170128)
49. Fukumoto Y, Matoba T, Ito A, Tanaka H, Kishi T, Hayashidani S, et al. Acute vasodilator effects of a Rho-kinase inhibitor, fasudil, in patients with severe pulmonary hypertension. Heart 2005; 91:391-392. (Pubitemid 40299237)
50. Masumoto A, Hirooka Y, Shimokawa H, Hironaga K, Setoguchi S, Takeshita A. Possible involvement of Rho-kinase in the pathogenesis of hypertension in humans. Hypertension 2001; 38:1307-1310. (Pubitemid 34033407)
51. Büssemaker E, Herbrig K, Pistrosch F, Palm C, Passauer J. Role of Rhokinase in the regulation of vascular tone in hypertensive renal transplant recipients. Atherosclerosis 2009; 207:567-572.
52. Nohria A, Grunert ME, Rikitake Y, Noma K, Prsic A, Ganz P, et al. Rho kinase inhibition improves endothelial function in human subjects with coronary artery disease. Circ Res 2006; 99:1426-1432. (Pubitemid 44949679)